ABBV STOCK HITS RECORD ALL TIME HIGH

Discussion in 'AbbVie' started by anonymous, Jun 14, 2017 at 12:17 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Alright Francis....
     

  2. anonymous

    anonymous Guest

    And so it comes to pass Ha Hah Hah Told Y'all
    AbbVie Inc. ABBV, -10.64% shares dropped 11.7% in early trade Thursday after the company said it will not try for accelerated approval of rovalpituzumab tesirine in third-line relapsed/refractory small cell lung cancer based on the drug's results in a phase 2 trial and the "magnitude of effect across multiple parameters." The decision was made after consulting with the Food and Drug Administration,the company said. AbbVie said it does still believe the drug, also called Rova-T, has potential in small cell lung cancer and other cancers expressing the DLL3 protein, and Rova-T continues to be studied in ongoing phase 3 trials for first-line and second-line small cell lung cancer. AbbVie bought Rova-T in a $5.8 billion deal for Stemcentrx in 2016; Rova-T was the company's lead asset. AbbVie shares have surged 14.5% over the last three months but dropped nearly 3% month-to-date. The S&P 500 SPX, -1.06% has surged 1.1% over the last three months and declined 0.1% month-to-date.
     
  3. anonymous

    anonymous Guest

    AbbVie Inc
    NYSE: ABBV - Mar 22,

    $100.06 USD DOWN $12.39 (11.02%) YUGE LOSS
    This is terrible news and it going to get worse when the other cat gets left out of the bag
    $60s HERE WE COME
     
  4. anonymous

    anonymous Guest

    F YOU !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! THIS IS FAKE NEWS AND ABBV WILL BE AT RECORD HIGH ASAP !!!!
    STOP SCARRING US !!!!!!!!! YOU FONY IDIOT !!!!!!!!!!!!!!!!!! ABBV IS DOING FINE !!!!! F YOU
     
  5. anonymous

    anonymous Guest

    AbbVie Inc
    NYSE: ABBV - Mar 22
    $96.31 USD
    DOWN -$16.11 (14.33%)

    Board of Directors Should Fire RICK RIGHT NOW !
    You folks don't realize how close ABBV is to financial disaster.
    Humira patent expiration is looming, and there's other trial data similar to Rova T
    that will bring Abbvie to its knees. Wait and see !!!!
     
  6. anonymous

    anonymous Guest

    AbbVie has $9.3B in cash on the books. This is offset by $6.42B in current liabilities. On the balance sheet. the debt has been growing. With $70.79B in total assets, balanced by $65.69B billion in total liabilities shows the viability of the company under any number of imagined business contexts. Rick needs to be fired and a shakeup in C Suite is called for. Too many bloodsucking leechs bleeding AbbVie. Time for a change and stockholders will demand it. I dumped 80% @ $115 last Friday as I knew about Rova T bust from inside sources. When the next few waves of bad news hits you're looking at $50-55 stock price.
     
  7. anonymous

    anonymous Guest

    Heard Upadacitinib had more adverse events. When it rains it pours !!
    Theres chatter on the street of Abbvie getting acquired. Heard this years ago and it never panned out
    With abbvies poor balance sheet and pending loss of Humira, things can happen in the blink of an eye.
     
  8. anonymous

    anonymous Guest


    ********************
    Please refer to your employee's handbook. Under Employee Rules #7 (paraphrasing) '..employees shall not engage in rumor mongering during work hours or in public domains...' You should cease posting total fabrications, possibly formulated by competition, regarding our company. You must realize that what you posted is nonsense.
    ********************
     
  9. anonymous

    anonymous Guest

    He probably wrote the handbook. You do understand you're responding to a former shot caller from Abbott labs?
     
  10. anonymous

    anonymous Guest

    You obviously aren't market savvy, just another Cafepharma troll!
     
  11. anonymous

    anonymous Guest

    a -25% decline in stock value in the past 3 weeks.... very very scary
     
  12. anonymous

    anonymous Guest


    Offsetting ricks stupidity by shorting this dog with my 8000 shares as many are. Got some nice long calls, may 90s 92.5s and shares at 90.37 quant buy signa. Sell May90 call for 6.90 buy may100 call 2.20 net credit of 4.70.SWEET
     
  13. anonymous

    anonymous Guest

    The stock is doing fine. STOP SCARING THE FOLKS HERE !!!!! Current price of $90.60 provides a very healthy EPS and expect many bargain hunters buying up ABBV.

    Again STOP SCARING PEOPLE !!!!

    YOU IGNORANT BLIVET !!!
     
  14. anonymous

    anonymous Guest

    numbers don't lie, no fake Ricky news
     
  15. anonymous

    anonymous Guest

    good hedge strategy
     
  16. anonymous

    anonymous Guest

    Indeed
     
  17. anonymous

    anonymous Guest

    If ABBV closes below $90, which is current floor support >>> Next level of support is $70.

    YIKES :(
     
  18. anonymous

    anonymous Guest

    Hey dickhead, ABBV will NEVER drop below 90 !!!
     
  19. anonymous

    anonymous Guest

    WTF.... market up hugely & ABBV down -1%,

    LOOKS LIKE HEDGE FUNDS ARE SELLING
     
  20. anonymous

    anonymous Guest

    Nah, only down (0.80%)